Literature DB >> 33563905

Antagonistic effects of IL-17 and Astragaloside IV on cortical neurogenesis and cognitive behavior after stroke in adult mice through Akt/GSK-3β pathway.

Li Sun1, Ruili Han1, Fei Guo1, Hai Chen1, Wen Wang2, Zhiyang Chen1, Wei Liu1, Xude Sun3, Changjun Gao4.   

Abstract

We aimed to investigate the exact effect of IL-17 on regulating neural stem cells (NSCs) stemness and adult neurogenesis in ischemic cortex after stroke, how Astragaloside IV(As-IV) regulated IL-17 expression and the underlying mechanism. Photochemical brain ischemia model was established and IL-17 protein expression was observed at different time after stroke in WT mice. At 3 days after stroke, when IL-17 expression peaked, IL-17 knock out (KO) mice were used to observe cell proliferation and neurogenesis in ischemic cortex. Then, As-IV was administered intravenously to assess cell apoptosis, proliferation, neurogenesis, and cognitive deficits by immunochemistry staining, western blots, and animal behavior tests in WT mice. Furthermore, IL-17 KO mice and As-IV were used simultaneously to evaluate the mechanism of cell apoptosis and proliferation after stroke in vivo. Besides, in vitro, As-IV and recombinant mouse IL-17A was administered, respectively, into NSCs culture, and then their diameters, viable cell proliferation and pathway relevant protein was assessed. The results showed knocking out IL-17 contributed to regulating PI3K/Akt pathway, promoting NSCs proliferation, and neurogenesis after ischemic stroke. Moreover, As-IV treatment helped inhibit neural apoptosis, promote the neurogenesis and eventually relieve mice anxiety after stroke. Unsurprisingly, IL-17 protein expression could be downregulated by As-IV in vivo and in vitro and they exerted antagonistic effect on neurogenesis by regulating Akt/GSK-3β pathway, with significant regulation for apoptosis. In conclusion, IL-17 exerts negative effect on promoting NSCs proliferation, neurogenesis and cognitive deficits after ischemic stroke, which could be reversed by As-IV.

Year:  2020        PMID: 33563905     DOI: 10.1038/s41420-020-00298-8

Source DB:  PubMed          Journal:  Cell Death Discov        ISSN: 2058-7716


  47 in total

1.  Silencing of PTGS2 exerts promoting effects on angiogenesis endothelial progenitor cells in mice with ischemic stroke via repression of the NF-κB signaling pathway.

Authors:  Zheyi Zhou; Changjun Lu; Shuhui Meng; Linglu Dun; Nannan Yin; Hongwei An; Hong Xu; Guocheng Liu; Yefeng Cai
Journal:  J Cell Physiol       Date:  2019-06-21       Impact factor: 6.384

Review 2.  Role of IL-17A signalling in psoriasis and associated bone loss.

Authors:  Özge Uluçkan; Erwin F Wagner
Journal:  Clin Exp Rheumatol       Date:  2016-07-20       Impact factor: 4.473

3.  Combination of PTH (1-34) with anti-IL17 prevents bone loss by inhibiting IL-17/N-cadherin mediated disruption of PTHR1/LRP-6 interaction.

Authors:  Mohd Nizam Mansoori; Priyanka Shukla; Divya Singh
Journal:  Bone       Date:  2017-09-19       Impact factor: 4.398

4.  Non-invasive Vagus Nerve Stimulation Protects Against Cerebral Ischemia/Reperfusion Injury and Promotes Microglial M2 Polarization Via Interleukin-17A Inhibition.

Authors:  Xiao-Ping Zhao; Yuan Zhao; Xiao-Ya Qin; Li-Yuan Wan; Xiao-Xuan Fan
Journal:  J Mol Neurosci       Date:  2018-11-27       Impact factor: 3.444

5.  Interleukin 17A inhibits autophagy through activation of PIK3CA to interrupt the GSK3B-mediated degradation of BCL2 in lung epithelial cells.

Authors:  Hong Liu; Su Mi; Zhe Li; Fang Hua; Zhuo-Wei Hu
Journal:  Autophagy       Date:  2013-03-20       Impact factor: 16.016

6.  Antagonistic effects of IL-17 and D-resolvins on endothelial Del-1 expression through a GSK-3β-C/EBPβ pathway.

Authors:  Tomoki Maekawa; Kavita Hosur; Toshiharu Abe; Alpdogan Kantarci; Athanasios Ziogas; Baomei Wang; Thomas E Van Dyke; Triantafyllos Chavakis; George Hajishengallis
Journal:  Nat Commun       Date:  2015-09-16       Impact factor: 14.919

7.  IL-17A deficiency promotes periosteal bone formation in a model of inflammatory arthritis.

Authors:  Anita T Shaw; Yukiko Maeda; Ellen M Gravallese
Journal:  Arthritis Res Ther       Date:  2016-05-10       Impact factor: 5.156

Review 8.  Neuroinflammation as a target for treatment of stroke using mesenchymal stem cells and extracellular vesicles.

Authors:  Sylwia Dabrowska; Anna Andrzejewska; Barbara Lukomska; Miroslaw Janowski
Journal:  J Neuroinflammation       Date:  2019-09-12       Impact factor: 8.322

Review 9.  Th17 and Cognitive Impairment: Possible Mechanisms of Action.

Authors:  Virginia Cipollini; Josef Anrather; Francesco Orzi; Costantino Iadecola
Journal:  Front Neuroanat       Date:  2019-11-19       Impact factor: 3.856

10.  The Delta-Subunit Selective GABA A Receptor Modulator, DS2, Improves Stroke Recovery via an Anti-inflammatory Mechanism.

Authors:  Silke Neumann; Lily Boothman-Burrell; Emma K Gowing; Thomas A Jacobsen; Philip K Ahring; Sarah L Young; Karin Sandager-Nielsen; Andrew N Clarkson
Journal:  Front Neurosci       Date:  2019-10-29       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.